NASDAQ:RARX - Ra Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.36 +0.78 (+5.01 %)
(As of 09/23/2018 04:13 AM ET)
Previous Close$16.36
Today's Range$15.0167 - $16.45
52-Week Range$4.78 - $17.90
Volume626,589 shs
Average Volume225,060 shs
Market Capitalization$503.86 million
P/E Ratio-6.79
Dividend YieldN/A
Beta2.02
Ra Pharmaceuticals logoRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Debt-to-Equity RatioN/A
Current Ratio11.61
Quick Ratio11.61

Price-To-Earnings

Trailing P/E Ratio-6.79
Forward P/E Ratio-7.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.93 million
Price / Sales107.32
Cash FlowN/A
Price / CashN/A
Book Value$3.06 per share
Price / Book5.35

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-54,430,000.00
Net MarginsN/A
Return on Equity-70.54%
Return on Assets-63.17%

Miscellaneous

Employees63
Outstanding Shares32,340,000
Market Cap$503.86 million

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.49) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.01. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

6 analysts have issued 12-month price targets for Ra Pharmaceuticals' stock. Their predictions range from $17.00 to $25.00. On average, they expect Ra Pharmaceuticals' stock price to reach $19.60 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

What is the consensus analysts' recommendation for Ra Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ra Pharmaceuticals.

Who are some of Ra Pharmaceuticals' key competitors?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 60)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 54)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 41)
  • Dr. Simon Read, Chief Scientific Officer (Age 47)
  • Mr. Alonso Ricardo, Sr. VP of R&D

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.76%), First Manhattan Co. (2.41%), Citadel Advisors LLC (1.08%), Millennium Management LLC (0.77%), Dimensional Fund Advisors LP (0.66%) and Northern Trust Corp (0.47%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Enterprise Associates 13 L New, Harry R Weller, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Ra Pharmaceuticals.

Which major investors are selling Ra Pharmaceuticals stock?

RARX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Northern Trust Corp, Alps Advisors Inc. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Ra Pharmaceuticals.

Which major investors are buying Ra Pharmaceuticals stock?

RARX stock was purchased by a variety of institutional investors in the last quarter, including First Manhattan Co., BlackRock Inc., FMR LLC, Dimensional Fund Advisors LP, Bank of America Corp DE, Citadel Advisors LLC, Nisa Investment Advisors LLC and Gabelli Funds LLC. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Harry R Weller, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $16.36.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $503.86 million and generates $4.93 million in revenue each year. The company earns $-54,430,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Ra Pharmaceuticals employs 63 workers across the globe.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is http://www.rapharma.com.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel